US terminates Moderna contract for investigational bird flu vaccine
HQ Team May 29, 2025: The US Department of Health and Human Services has terminated a contract awarded to Moderna Inc. for the.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team May 29, 2025: The US Department of Health and Human Services has terminated a contract awarded to Moderna Inc. for the.
HQ Team May 29, 2025: More than one million children are at risk of contracting cholera in war-torn Sudan, where 185 deaths have.
HQ Team May 28, 2025: GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract.
HQ Team May 28, 2025: The US drug regulator halted Rocket Pharmaceuticals Inc.’s investigational gene therapy for Danon disease after a patient died.
HQ Team May 28, 2025: Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor.
HQ Team May 24, 2025: The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive.
HQ Team May 22, 2025: Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies.
HQ Team May 21, 2025: Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total.
HQ Team May 21, 2025: The Food and Drug Administration has come out with new product-specific guidances for developing generic drugs and generating.
HQ Team May 20, 2025: Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe.